Bioengineering Kidneys What Is the Outlook?
Usama Nihad Rifat*
Department of Urology and Kidney Transplantation, University of Baghdad Dean, Medical City Hospital, Baghdad, Iraq
*Corresponding author: Usama Nihad Rifat, Fellow of the Royal Society of Medicine, Department of Urology and Kidney Transplantation, Iraqi Board of Medical Specializations, Baghdad, Iraq. Tel: +962799594954; Email: usama.rifat@yahoo.com
Received
Date: 13 September, 2017; Accepted Date: 13 September,
2017; Published Date: 20 September, 2017
Citation: Rifat UN (2017) Bioengineering Kidneys What Is the Outlook? J Urol Ren Dis 2017: 155. DOI: 10.29011/2575-7903.000155
Editorial
End-Stage Renal Disease (ESRD) is common. Transplantation is the only curative treatment [1]. However, waiting times have increased. To create a bioengineered kidney a scaffold is needed with cell attachment. Native and cadaveric kidneys could be used. Decellularization of kidneys is performed by using detergent perfusion. Vascular, glomerular, and tubular components will stay intact. Decellularization leads to loss of Cell-Mediated functions. Scaffolds are repopulated with endothelial and epithelial cells. These cells come from human umbilical venous endothelial cells and rat neonatal kidney cells through the ureter. Studies showed that the renal papilla is a niche for adult kidney stem cells and is involved in organ maintenance and repair after injury [2]. Allogeneic transplantation is effected by donor shortage; surgical morbidity and the need for immunosuppression [3].
Sheep
kidneys comprise a suitable source [4]. These can
be seeded with human cells, and then used. Rhesus monkey kidney could also be
used [5]. Since the kidney is derived from the
ureteric bud and the metanephrogenic mesenchyme [6],
single metanephric mesenchymal cell can generate all the epithelial cells of
the nephron (except the collecting duct), Renal stem cells are not suitable for
whole kidney regeneration. Quite the opposite, mesenchymal stem cells are
accessible, e.g from adipose tissue and they do not need technical handling [7]. Internationally the donor organs meet about
one-fifth of the need. Regenerative medicine is a potential option [8]. We are looking forward to the availability in the
near future of kidneys and other organs as they become on demand. We are
expecting shorter waiting lists and unnecessary
immunosuppression.